Separating Agent for Human Serum IgG Antibodies
Summary
The European Patent Office published application EP3375875A1, a patent for a separating agent for human serum-derived IgG polyclonal antibodies and the method of separation. The applicants are National University Corporation, Kyoto Institute of Technology, and Daicel Corporation. The invention covers IPC classifications C07K, C12N, and C12Q related to immunoglobulin separation.
What changed
EPO published patent application EP3375875A1 for a separating agent and method for human serum-derived IgG polyclonal antibodies. The patent names three inventors and covers designated European states including DE, FR, GB, IT, NL, ES, and other EPC contracting states.
For biotechnology companies developing antibody purification processes or IgG fractionation products, this patent represents potential freedom-to-operate considerations. Manufacturers of serum-derived IgG products should review their processes against the claims in this published application.
Archived snapshot
Apr 22, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
SEPARATING AGENT FOR HUMAN SERUM-DERIVED IGG POLYCLONAL ANTIBODIES, AND METHOD FOR SEPARATING HUMAN SERUM-DERIVED IGG POLYCLONAL ANTIBODIES USING SAME
Publication EP3375875A1 Kind: A1 Apr 15, 2026
Applicants
National University Corporation
Kyoto Institute of Technology, Daicel Corporation
Inventors
KUMADA, Yoichi, HASEGAWA, Yuya, UCHIMURA, Seiichi
IPC Classifications
C12N 15/09 20060101AFI20250610BHEP C07K 1/22 20060101ALI20250610BHEP C07K 16/42 20060101ALI20250610BHEP C12Q 1/70 20060101ALI20250610BHEP C07K 16/06 20060101ALI20250610BHEP C12N 15/62 20060101ALI20250610BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.